Mehra R - Search Results

1

The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.

Mehra R, Cohen RB, Burtness BA. Mehra R, et al. Clin Adv Hematol Oncol. 2008 Oct;6(10):742-50. Clin Adv Hematol Oncol. 2008. PMID: 18997665 Free PMC article. Review.

2

Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.

Mehra R, Murren J, Chung G, Smith B, Psyrri A. Mehra R, et al. Clin Colorectal Cancer. 2005 May;5(1):61-4. doi: 10.3816/ccc.2005.n.018. Clin Colorectal Cancer. 2005. PMID: 15929808

3

The second annual symposium on the future of lung cancer: a translational focus. 11-12 November 2005, Washington D.C., USA.

Mehra R. Mehra R. Expert Opin Ther Targets. 2006 Jun;10(3):475-80. doi: 10.1517/14728222.10.3.475. Expert Opin Ther Targets. 2006. PMID: 16706687

4

Incidence and management of bevacizumab-related toxicities in colorectal cancer.

Saif MW, Mehra R. Saif MW, et al. Among authors: mehra r. Expert Opin Drug Saf. 2006 Jul;5(4):553-66. doi: 10.1517/14740338.5.4.553. Expert Opin Drug Saf. 2006. PMID: 16774493 Review.

5

Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials.

Mehra R, Burtness B. Mehra R, et al. Expert Opin Biol Ther. 2006 Sep;6(9):951-62. doi: 10.1517/14712598.6.9.951. Expert Opin Biol Ther. 2006. PMID: 16918262 Review.

6

EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.

Mehra R, Cohen RB, Harari PM. Mehra R, et al. Curr Oncol Rep. 2008 Mar;10(2):176-84. doi: 10.1007/s11912-008-0027-6. Curr Oncol Rep. 2008. PMID: 18377832 Review.

7

New agents in the treatment for malignancies of the salivary and thyroid glands.

Mehra R, Cohen RB. Mehra R, et al. Hematol Oncol Clin North Am. 2008 Dec;22(6):1279-95, xi. doi: 10.1016/j.hoc.2008.08.010. Hematol Oncol Clin North Am. 2008. PMID: 19010274 Free PMC article. Review.

8

Current issues in adjuvant chemotherapy for resected, stage IB non-small-cell lung cancer.

Borghaei H, Mehra R, Simon G. Borghaei H, et al. Among authors: mehra r. Future Oncol. 2009 Feb;5(1):19-22. doi: 10.2217/14796694.5.1.19. Future Oncol. 2009. PMID: 19243293 No abstract available.

9

Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer.

Rusthoven KE, Feigenberg SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge J, Swing R, Lango M, Cohen R, Jimeno A, Chen C. Rusthoven KE, et al. Among authors: mehra r. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1020-5. doi: 10.1016/j.ijrobp.2009.09.003. Epub 2010 Mar 16. Int J Radiat Oncol Biol Phys. 2010. PMID: 20231078 Clinical Trial.

10

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer.

Tejani MA, Cohen RB, Mehra R. Tejani MA, et al. Among authors: mehra r. Biologics. 2010 Aug 9;4:173-85. doi: 10.2147/btt.s3050. Biologics. 2010. PMID: 20714355 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results